

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** James H. Aylward

**Examiner:** C. Tate

**Serial No:** 09/888,178

**Art Unit:** 1654

**Filed:** June 21, 2001

**Docket:** 14923Z

**For:** ANTI-CANCER COMPOUNDS

**Dated:** January 3, 2003

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
JAN 07 2003  
TECH CENTER 1600/2900  
#8  
B.9  
2/4/03

**RESPONSE**

Sir:

In response to the Restriction Requirement dated December 3, 2003, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, applicant provisionally elects the subject matter of Group I, i.e., Claims 33-89 and 94-99, for continued examination herein.

**REMARKS**

Claims 33-99 are pending in the above-identified application and have been subjected to a Restriction Requirement under 35 U.S.C. §121 as follows:


"I. Claims 33-89 and 94-99, drawn to a method of treating cancer  
using a singular compound, classified in class 514, subclass 100+.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on **January 3, 2003**.

Dated: January 3, 2003

  
Mishelle Mustafa